Axcan Pharma Inc

597 Laurier Blvd, Mont Saint-Hilaire, Quebec CANADA J3H 6C4 La Prévôté - Route du Bû 78550 Houdan, FRANCE 22 Inverness Center Parkway Birmingham, AL 35242

By combining the successes of our internal research and development efforts with our product-licensing strategy, we have built a strong research and development pipeline filled with promising products. Our diverse pipeline mitigates the risks of drug development because we have a balanced mix of both short-and long-term opportunities in the development of products for various functions of the gastrointestinal system.

BioCryst Pharmaceuticals Inc
(BCRX) 5.18

2190 Parkway Lake Drive, Birmingham, AL 35244

Biocryst Pharmaceuticals develops pharmaceuticals for the treatment of infections, inflammatory and cardiovascular diseases and disorders. The Company uses structured-based drug design technologies to develop small-molecule pharmaceuticals for the treatment of diseases and disorders. The Company has seven products under development, of which influenza neuraminidase inhibitor, RWJ-270201, has been licensed to The R.W. Johnson Pharmaceuticals Research Institute and Ortho-McNeil Pharmaceutical, Inc for clinical development. The products under development include neuraminidase inhibitor, PNP inhibitor, complement inhibitors, Hemagglutinin-neuraminidase inhibitors, tissue factor/VIIa inhibitors, Hepatitis C polymerase inhibitors and rhinovirus polymerase inhibitors.

Bioheart

2400 North Commerce Parkway, Suite 408, Weston, FL 33326

Bioheart has established, and is continuing to develop, what we believe will be the premier portfolio of intellectual property and proprietary technologies in the field of heart muscle regeneration. Dr. Taylor, who is working with Bioheart, is recognized as the leading scientist in the field of heart muscle tissue regeneration and has shown that the use of immature myoblasts is fundamentally key to the success of the procedure. We also have various agreements in place covering patents and technologies developed by other leading scientists relating to heart muscle regeneration and other treatments of cardiovascular disease, including agreements with Ray Chiu, M.D. of McGill University and others. Bioheart has acquired exclusive rights to the Schmidt Patent US 5,972,013 covering the basic design of a deflecting guide catheter with slideable injection needle. This positions Bioheart as the leader of endovascular delivery systems for cells and genes directly into the heart. Data continues to be gathered to support entry to human trials. Bioheart has acquired Dr. Laurace Townsend’s patents covering the use of cardiomyocytes cultured to be reinjected for ventricular myocardium repair. Bioheart has also acquired the exclusive rights to key additives such as Nitric Oxide Synthase and L-Arginine, for improving arteriogenesis to better feed the new muscle we create with myoblasts.

CryoLife Inc
(CRY) 5.57

1655 Roberts Blvd., NW Kennesaw, GA 30144

Founded in 1984, CryoLife®, Inc. was the first biomedical company to commercially develop low temperature preservation of human tissues for implant. With the founding of CryoLife, preserved human tissue became available for cardiac, vascular and orthapaedic surgical reconstruction. The Company's proprietary processes for preserving human heart valves, veins and connective tissue have dramatically improved and enhanced the lives of tens of thousands of patients. In 1995, CryoLife acquired the rights to the O'Brien Stentless Aortic Porcine Bioprostheses. These clinically proven products represent the "state-of-the-art" in xenograft technology and bring a new and complementary dimension to CryoLife's commitment to improving the quality of life for patients who require such devices. The Company acquired the Ross pulmonary porcine heart valve in 1997. Both of these valves are manufactured in Marietta, Georgia. CryoLife's Research Staff has developed a tissue engineered heart valve and vascular graft replacement called the SynerGraft® family of products. The Company has also developed a bioadhesive product, BioGlue®, for use in aortic dissections.

DNAPrint Genomics Inc
*SERVICE*

1621 West University Parkway, Sarasota, FL 34243

DNAPrint Genomics, Inc. is an applied science company focused on the development and marketing of innovative genetic testing products and services. Our scientists aim their research towards discovery of DNA analysis solutions to serve clients in Forensic Science, Genealogical Research, and Pharmaceutical development.

DOR Biopharma
(SNGX.OB) 0.23

1101 Brickell Avenue, Suite 701 South, Miami, FL 33131

DOR BioPharma, Inc. is a biopharmaceutical company developing products for life-threatening side effects of cancer treatments, serious gastrointestinal diseases, and bioterrorism. Our lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally-acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of bone marrow transplantation. DOR BioPharma has recently filed a New Drug Application (NDA) with the FDA for orBec® for the treatment of GI GVHD. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation.

Expression Genetics, Inc.

2215 Mock Road, Huntsville, AL 35801

EGEN is a specialty biopharmaceutical company developing safe and efficient polymeric delivery systems to be used to create products for treatment of human diseases. Our delivery vehicles, based on a synthetic biocompatible polymeric system can be used to deliver therapeutic genes, inhibitory RNA (siRNA & shRNA) and small molecules. The delivery systems function by protecting the therapeutic cargo from degradation, promoting uptake by the target cells and facilitating intracellular trafficking. Unique polymer chemistry and formulation strategies, designed to overcome delivery barriers, are the distinguishing characteristics of EGEN’s proprietary technology, and differ substantially from other approaches. The lead product based on our TheraPlas™ technology (delivery of a therapeutic plasmid with a safe and efficient plasmid delivery system) has recently successfully completed a Phase I clinical trial, and is proceeding into expanded human testing. Our TheraSilence™ technology platform (delivery of therapeutic siRNA or shRNA with a safe and efficient RNAi delivery system) has produced novel candidates that are being tested for proof of concept in animal models of diseases.

Inhibitex
(INHX) 1.75

9005 Westside Parkway, Alpharetta, GA 30004

We are a biopharmaceutical company focused on the development of products that can treat, prevent or diagnose serious infections. We currently have two products in development based upon MSCRAMM® antibody technology. MSCRAMM® proteins are located on the surface of pathogenic organisms, such as bacteria and fungi, and play a prominent role in the process of infection. These proteins enable organisms to initiate and maintain an infection by adhering to specific sites on human tissue or implanted medical devices. Our antibody-based product candidates are being developed for diagnostics, vaccines and treatment of hospital-acquired infections. Aurexis® is a clinical stage monoclonal antibody in development for first-line therapy, in combination with standard of care antibiotics, to treat serious Staphylococcus aureus (S. aureus) bloodstream infections in hospitalized patients. We also have a license and collaboration agreement with Wyeth to develop vaccines against staphylococcal organisms. We have recently licensed our MSCRAMM® technology to 3M for the development of diagnostics to detect clinically relevant pathogenic organisms. n April, 2007 the Company announced that it had entered into a definitive agreement to merge with FermaVir Pharmaceuticals, Inc. FermaVir adds two new programs that include FV-100, a highly potent nucleoside analogue for the treatment of herpes zoster infections ("shingles"), and a series of preclinical compounds for the treatment of human cytomegalovirus (CMV) disease.

Martek Biosciences Corp
(MATK) 22.31

6480 Dobbin Road, Columbia, MD 21045 PO Box 5000, 1416 N. Williamsburg County Hwy, Kingstree, SC 29556

Martek Biosciences Corporation is a leading innovator in the development of nutritional products that promote health and wellness through every stage of life. Martek has become a leader in fermentation technology and is an innovator in the research and development of products derived from microalgae. Martek has developed and patented two fermentable strains of microalgae which produce oils rich in docosahexaenoic acid, DHA. A similar patented process was developed for a fungus that produces an oil rich in arachidonic acid, ARA. Both DHA and ARA are important nutrients for optimal infant development, while DHA has health benefits that extend throughout life.

Nabi Biopharmaceuticals
(NABI) 4.83

5800 Park of Commerce Blvd., N.W., Boca Raton, FL 33487 12276 Wilkins Avenue, Rockville, MD 20852

Nabi Biopharmaceuticals is focused on developing and marketing products that address unmet medical needs and offer commercial opportunities in our core business areas: Hepatitis and transplant, Gram-positive bacterial infections and nicotine addiction. We are a fully-integrated biopharmaceutical company with our own facilities and employees to develop products (R&D); test, process and utilize antibodies collected at our antibody collection centers; manufacture products; and market and sell products.

Noven Pharmaceuticals Inc
(NOVN) 0.00

11960 S.W. 144th Street, Miami, FL 33186

Noven Pharmaceuticals, Inc. is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Together with Novartis Pharmaceuticals Corporation, Noven owns a highly profitable women's health products company called Novogyne Pharmaceuticals. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-DotÆ, licensed to Novogyne, and EstradotÆ, licensed to Novartis Pharma AG) and combination estrogen/progestin transdermal delivery systems (including CombiPatchÆ, licensed to Novogyne, and EstalisÆ, licensed to Novartis Pharma AG). With a range of additional products in development, including MethyPatchÆ, Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal drug delivery systems.

Regeneration Technologies
(RTIX) 2.11

11621 Research Circle, Alachua, FL 32615

Regeneration Technologies prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in spine, sports medicine and other orthopedic surgeries. Biologic implants are very effective in repairing and promoting the healing of a wide variety of bone and other tissue defects.

Theragenics Corporation
(TGX) 1.18

203 Bristol Industrial Way, Buford, GA 30518

Theragenics Corporation® is a medical device company serving the cancer treatment and surgical markets. The Company’s brachytherapy business manufactures and markets seeding devices that are primarily used in the minimally invasive treatment of localized prostate cancer.

Viragen, Inc.
(VRAI.PK) 0.00

865 SW 78th Avenue, Suite 100, Plantation, FL 33324

Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins.

Xcelience
*SERVICE*

5415 West Laurel Street, Tampa, FL 33607

Xcelience is an independent formulation development company, providing customized global solutions to the biotechnology and pharmaceutical industries. Xcelience takes the creative and strategic approach to compound development, utilizing our expertise in the analysis, pre-formulation, formulation and manufacturing programs of drug development, and maximizing the efforts needed to deliver your product to market. Xcelience is committed to serving the needs of our clients in a timely, efficient, and well managed process that is fully integrated and unparalleled in the industry.